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iWith health care reform and pay-for-performance measures
in the near future, the heart failure (HF) community must
critically appraise our practice patterns and processes of
care. Ideally, our efforts begin with strategies to prevent
HF, followed by therapies to treat HF and approaches to
improving the cost-effectiveness of care. It is increasingly
apparent that our current model is not sustainable, and
we look to the scientists and clinicians in our field to
provide innovative yet practical solutions. Herein, we
discuss the major published clinical advances in HF over
the past academic year (July 2010 to June 2011), includ-
ing guidelines and scientific statements in Table 1 (1–9),
state-of-the-art reviews in Table 2 (10–20), and key
linical trials in Table 3 (21–28).
pidemiology, Risk Profiling, and Prevention
n the United States, HF incidence approaches 10 per 1,000
opulation after 65 years of age (29). Efforts to prevent HF
ocus on the treatment of established risk factors and the
evelopment of risk scores to predict incident HF. One risk
rediction score, the Health ABCHeart Failure Model, was
alidated externally in Cardiovascular Health Study partic-
pants, confirming the utility of 9 variables to predict
ncident HF. The strength of the model is its applicability
o real-world practice, in which all of the variables are
eadily available (30). A separate study suggested that
ncluding only common cardiovascular risk factors (coronary
isease, hypertension, diabetes, atrial fibrillation, valvular
isease, and age) can predict incident HF in men and
omen during 1,015,794 person-years of follow-up (31).
am et al. (32) showed that after adjustment for cardiac
ysfunction, subclinical dysfunction in each noncardiac organ
ystem was associated with a 30% increased risk for HF.
Nevertheless, there is an unmet need to predict risk
arlier. A small study by Yan et al. (33) reported the use of
ardiac magnetic resonance imaging to detect subclinical,
egional left ventricular (LV) dysfunction, as an indepen-
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20, 2011, accepted January 21, 2012.ent predictor for incident HF and cardiovascular events in
he asymptomatic, lower risk MESA (Multi-Ethnic Study
f Atherosclerosis) cohort. Another investigation of an
lderly cohort revealed an increased risk for LV diastolic
ysfunction, independent of LV mass and traditional risk
actors, that occurred with increased body mass index (34).
hese studies suggest that lifestyle counts in HF prevention
fforts. Indeed, an analysis of almost 60,000 Finnish subjects
ree of HF at baseline showed that moderate and high levels
f occupational and leisure-time physical activity were
ssociated with a reduced risk for HF (35).
iomarkers
his year saw no new evidence that serial biomarker-guided
anagement of HF could reduce morbidity or mortality. In
oth the STARBRITE (Strategies for Tailoring Advanced
F Regimens in the Outpatient Setting) and PRIMA (Can
ro-Brain-Natriuretic Peptide Guided Therapy of Chronic
F Improve HF Morbidity and Mortality) trials, the use of
atriuretic peptide–guided therapy was associated with
ncreased use of evidence-based medications but no im-
rovement in days alive or decrease in HF hospitalizations
36,37).
Several biomarker studies focused on predicting HF
ncidence in the community. Elevated cardiac troponin T
easured using a highly sensitive assay was associated with
ncreased risk for coronary heart disease, mortality, and
ncident HF (hazard ratio [HR] for HF: 5.95; 95% confi-
ence interval [CI]: 4.47 to 7.92) after adjustment for
raditional risk factors, kidney function, C-reactive protein,
nd N-terminal pro–brain natriuretic peptide. Surprisingly,
easurable cardiac troponin T levels were detected in 66.5%
f the 9,698 subjects in this study, all of whom were general
articipants in the ARIC (Atherosclerosis Risk in Commu-
ities) study, age 54 to 74 years (38). A similar study
nvestigated the association between the highly sensitive
ardiac troponin T assay and incident HF in adults from the
HS (Cardiovascular Health Study) age 65 years, finding
strikingly similar percent of patients with detectable levels
f troponin (66.2%). Furthermore, they found that 50%
ncreases in troponin T in subjects who had undetectable
evels at baseline were associated with an increased risk for
ncident HF (39). Multimarker strategies for predicting risk
or HF were studied in 2 cohorts. In the Framingham
360 Owens and Jessup JACC Vol. 60, No. 5, 2012
The Year in Heart Failure July 31, 2012:359–68cohort, brain natriuretic peptide
and urinary albumin/creatinine
ratio provided incremental risk
prediction to classic risk factors
(40). In the Malmo Diet and
Cancer Study cohort, only the
natriuretic peptides improved
risk prediction over standard fac-
tors (41). These publications, re-
flecting a limitation of many bio-
marker studies, beg the question
of what therapeutic strategy
could be implemented early, in a
pre-clinical stage, to mitigate risk
for HF.
Pathophysiology
The link between iron deficiency
and HF continued to be a much
investigated topic. In a prospective, observational cohort of
patients with chronic systolic HF, iron deficiency was more
prevalent in women and in those with advanced New York
Heart Association (NYHA) functional class and higher
biomarker levels. In multivariate models, iron deficiency was
significantly associated with increased risk for death or
transplantation (adjusted HR: 1.58; 95% CI: 1.14 to 2.17;
p  0.01) (42). In a separate study, Maeder et al. (43)
investigated the link between anemia and HF severity,
reporting reduced myocardial iron content in patients with
HF compared with controls. Additionally, catecholamines
and aldosterone both down-regulated the myocardial mes-
senger ribonucleic acid expression of the type 1 transferrin
receptor, suggesting a mechanistic link (43).
Genetics and genomics. A thorough review of inherited
cardiomyopathies was published by Watkins et al. (44),
highlighting our growing knowledge of the overlap between
genes that cause structurally distinct inherited cardiomyop-
athies. An additional study from the German Competence
Network Heart Failure (45) was likewise contributory.
Given the genetic basis of some cardiomyopathies, it is
imperative for clinicians to perform screening protocols for
at-risk family members, with adjunctive genetic counseling
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CI  confidence interval
CRT  cardiac
resynchronization therapy
HF  heart failure
HFNEF  heart failure with
normal ejection fraction
HR  hazard ratio
ICD  implantable
cardioverter-defibrillator
LV  left ventricular
NYHA  New York Heart
Association
VAD  ventricular assist
device
Guidelines and Scientific StatementsTable 1 Guidelines and Scientific Statements
“2010 Focused Update of ESC Guidelines on Device Therapy in Heart Failure” (1)
“Familial Evaluation in Arrhythmogenic Right Ventricular Cardiomyopathy: Impact of
“Genetic Counselling and Testing in Cardiomyopathies: A Position Statement of the
“HRS/EHRA Expert Consensus Statement on the State of Genetic Testing for the Ch
“Working Formulation for the Standardization of Definitions of Infections in Patients
“The ISHLT Working Formulation for Pathologic Diagnosis of Antibody-Mediated Reje
“Report From a Consensus Conference on Antibody-Mediated Rejection in Heart Tra
“A 2010 Working Formulation for the Standardization of Definitions of Infections in
“Recommendations for the Use of Natriuretic Peptides in Acute Cardiac Care: A Pos
ESC Working Group on Acute Cardiac Care” (8)EHRA  European Heart Rhythm Association; ESC  European Society of Cardiology; HRS  Hear Rhythand testing. To this end, guidelines from the European
Society of Cardiology (3), as well as a consensus statement
from the Heart Rhythm Society in conjunction with the
European Heart Rhythm Association (9), were published.
Management of HF
Acute decompensated HF. There are 3 million hospital-
izations for acute HF annually in the United States, 80% of
which arrive through emergency departments. Accordingly,
the National Heart, Lung, and Blood Institute published
the findings of a working group on emergency department
management of acute HF, which outlines the existing
opportunities and challenges (46). The search for pharma-
cological strategies to relieve acute HF continues, including
publication of the phase 3 PROTECT (Placebo-Controlled
Randomized Study of the Selective A1 Adenosine Receptor
Antagonist Rolofylline for Patients Hospitalized With
Acute Decompensated Heart Failure and Volume Overload
to Assess Treatment Effect on Congestion and Renal
Function) trial. In this randomized study of more than
2,000 patients, rolofylline was not found beneficial in
reducing symptoms or improving survival or renal function
(47,48). Disappointment continued with publication of the
randomized controlled ASCEND–HF (Acute Study of
Clinical Effectiveness of Nesiritide in Decompensated Heart
Failure). In this study of 7,000 patients, nesiritide was not
associated with a change in the rate of rehospitalization or
ics and Revised Task Force Criteria” (2)
an Society of Cardiology Working Group on Myocardial and Pericardial Diseases” (3)
pathies and Cardiomyopathies” (9)
Ventricular Assist Devices” (ISHLT) (4)
in Heart Transplantation: Evolution and Current Status (2005-2011)” (5)
tation” (ISHLT) (6)
thoracic Transplant Recipients” (ISHLT consensus statement) (7)
tatement from the Study Group on Biomarkers in Cardiology of the
State-of-the-Art ReviewsTable 2 State-of-the-Art Reviews
“Cirrhotic Cardiomyopathy” (10)
“Update 2011: Clinical and Genetic Issues in Familial Dilated Cardiomyopathy” (11)
“Exercise Training in Heart Failure: Practical Guidance” (12)
“The Role of Exercise Training in Heart Failure” (13)
“Heart Failure and Chronic Obstructive Pulmonary Disease” (14)
“Heart Failure With Preserved Ejection Fraction: Pathophysiology, Diagnosis, and
Treatment” (15)
“Medical and Surgical Treatment of Acute Right Ventricular Failure” (16)
“Obstructive Sleep Apnea and Heart Failure” (17)
“Pregnancy in Patients With Pre-Existing Cardiomyopathies” (18)
“Thromboembolism and Antithrombotic Therapy in Patients With Heart Failure in
Sinus Rhythm: Current Status and Future Directions” (19)
“Troponin Elevation in Heart Failure” (20)Genet
Europe
annelo
Using
ction
nsplan
Cardio
ition Sm Society; ISHLT  International Society for Heart and Lung Transplantation.
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July 31, 2012:359–68 The Year in Heart Failuredeath and had a nonsignificant effect on dyspnea (21). More-
over, the DOSE (Diuretic Optimization Strategies Evalua-
tion) trial showed no significant difference in symptoms or
renal function when loop diuretic therapy was administered by
continuous infusion or bolus and no significant difference in
outcomes at low versus high dose (23).
The combination of loop diuretic therapy and inotropes
was investigated in 60 patients in the DAD–HF (Dopamine
in Acute Decompensated Heart Failure) trial, which dem-
onstrated that the combination of a low-dose infusion of
furosemide with 5 g/kg/min of dopamine was as effective
as high-dose furosemide infusion on symptoms, length of
stay, rehospitalization, and 60-day mortality. Furthermore,
the combination of dopamine and low-dose furosemide was
associated with improved renal function (49).
Pharmacological therapy. There were a number of ran-
domized controlled trials investigating pharmacological
therapy for chronic systolic HF. The first, EMPHASIS-HF
(Eplerenone in Mild Patients Hospitalization and Survival
Study in Heart Failure), was stopped prematurely, after show-
ing that eplerenone reduced the risk for death and hospitaliza-
tion in patients with systolic HF andNYHA functional class II
symptoms. Serum potassium levels5.5 mmol/l were found in
1.8% of patients on eplerenone versus 7.2% on placebo (p 
.001) (24), suggesting that patient selection and monitoring
re still critical when prescribing aldosterone antagonists. A
uture strategy to mitigate hyperkalemia might include the
se of RLY5016, an oral potassium-binding polymer, the
fficacy and safety of which were suggested in a recent
andomized trial (25).
The SHIFT (Systolic Heart Failure Treatment With the
f Inhibitor Ivabradine) trial investigators reported a reduc-
ion in hospital admissions for HF (21% placebo vs. 16%
rug; HR: 0.74; 95% CI: 0.66 to 0.83; p  0.0001) and a
eduction in deaths due to HF (5% placebo vs. 3% drug;
R: 0.74; 95% CI: 0.58 to 0.94; p  0.014). It is important
Key Clinical Trials in Heart FailureFrom Academic Year 2010–2011Table 3 Key Cli ical Trials in Heart FailureFrom Academic Year 2010–2011
Trial n
Acute Study of Clinical Effectiveness of Nesiritide in Decompensated
Heart Failure (21)
7,141
CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve
Outcomes in NYHA Class III Heart Failure Patients (22)
550
Diuretic Optimization Strategies Evaluation (23) 308
Eplerenone in Mild Patients Hospitalization and Survival Study in Heart
Failure (24)
2,737
Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-
Group, Multiple-Dose Study to Evaluate the Effects of RLY5016 in
Heart Failure Patients (25)
120
Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (26) 1,798
Systolic Heart Failure Treatment With the If Inhibitor Ivabradine Trial (27) 6,558
SmartDelay Determined AV Optimization: A Comparison to Other AV
Delay Methods Used in CRT (28)
980
AV  atrioventricular; CRT  cardiac resynchronization therapy; NYHA  New York Heart
Association.o note that although approximately 90% of patients in thetudy were treated with beta-blockers, they were not max-
mally beta-blocked. A statistically significant number of
ubjects treated with ivabradine experienced symptomatic
radycardia and visual side effects compared with the
lacebo group (27). A follow-up study revealed that patients
ith heart rates lower than 60 beats/min in the drug-treated
roup had fewer events at 28 days than did those with
igher heart rates. After adjustment for change in heart rate,
he treatment effect was neutralized, suggesting that it is the
elective reduction in heart rate that may underlie the
eneficial effect of ivabradine (50). In a smaller, randomized
rial, Guazzi et al. (51) found a beneficial effect of sildenafil
n functional capacity and clinical status in patients with
YHA functional class II or III systolic HF. Moreover,
arameters of diastolic function also improved, with no
erious adverse events (51).
Two small studies suggested a potential role for n-3
olyunsaturated fatty acids in nonischemic cardiomyopathy
52) and testosterone in elderly women with advanced HF
53). Coenzyme Q10, a cofactor in mitochondrial oxidative
phosphorylation and generation of adenosine triphosphate,
was not found to be an independent prognostic variable in
HF, according to a pre-specified substudy of the CORONA
(Controlled Rosuvastatin Multinational Study in Heart
Failure) (54).
Chemotherapy-induced cardiomyopathy. The concerning
finding that many patients with chemotherapy-associated
cardiotoxicity are not receiving guideline-based pharmaco-
logical treatment for LV dysfunction was reported by Yoon
et al. (55). Of patients with ejection fractions 55% after
receiving chemotherapy, only 40% were treated with
angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers, and 51% were treated with beta-blockers.
The investigators noted an opportunity for collaboration
with oncologists to optimally manage these patients (55).
Strategies for detecting subclinical signs of LV dysfunction
are actively being investigated, including a study demon-
strating that longitudinal strain and high-sensitivity tro-
ponin I can predict subsequent development of cardiotox-
icity in patients who were treated with anthracyclines and
trastuzumab (56).
Surgical interventions. The STITCH (Surgical Treat-
ment for Ischemic Heart Failure) trial results were reported
by Velazquez et al. (57), demonstrating that coronary artery
bypass grafting (CABG) in addition to medical therapy did
not reduce mortality compared with medical therapy alone
in patients with LV dysfunction and coronary artery disease
amenable to CABG (HR with CABG: 0.86; 95% CI: 0.72
to 1.04; p  0.12). However, patients in the CABG arm
were less likely to die of cardiovascular causes (57).
Imaging. A substudy of the STITCH trial demonstrated
that the presence of myocardial viability using single-photon
emission computed tomography or dobutamine echocardi-
ography did not influence the likelihood of survival benefit
from CABG plus medical therapy versus medical therapy
alone. This substudy included 601 patients with LV dys-
362 Owens and Jessup JACC Vol. 60, No. 5, 2012
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onary artery disease amenable to CABG who underwent
viability testing at the discretion of the recruiting investiga-
tor (58). Publication of these results fueled the ongoing
controversy of when and how to use myocardial viability
testing. The use of late gadolinium enhancement in
cardiac magnetic resonance imaging for prognostication
and risk assessment in almost all types of cardiomyopathy
was reviewed by Mewton et al. (59).
Remote Patient Monitoring
Several studies added to our knowledge regarding remote
management and monitoring. A report of the long-term
follow-up from the DIAL (Randomized Trial of Phone
Intervention in Chronic Heart Failure) trial observed a
reduction in the rate of death or hospitalization for HF in
the intervention group at both 1 and 3 years, driven by a
reduction in hospitalizations. Interestingly, these positive
results may be attributed to the educational piece of the
intervention; patients who increased their adherence had
lower event rates (60). In contrast, 2 groups reported no
benefit of telemonitoring in patients with HF (61,62). In
the larger study, 1,653 patients with recent hospitalizations
were randomized to telemonitoring or usual care. The
intervention consisted of an interactive voice response
system that collected data but did not provide education.
There was no significant difference between the 2 groups
with respect to readmission for any cause, death, or any
secondary end point. One acknowledged limitation of
this trial was that 14% of patients randomized to the
intervention never used the telemonitoring system (61).
Additionally, the information gathered by telemonitoring
did not result in a uniformly prescribed change in
management strategy. In the smaller trial, again no
benefit was observed with a telemonitoring strategy that
did not include education (62).
Data gathered in the COMPASS–HF (Chronicle Offers
Management to Patients With Advanced Signs and Symp-
toms of Heart Failure) study, which used implantable
hemodynamic monitors, demonstrated chronically elevated
filling pressures in many patients. Furthermore, patients
enrolled had a progressive increase in risk for HF events
with higher chronic 24-h estimated pulmonary artery pres-
sure (event risk 20% at 18 mm Hg, 34% at 25 mm Hg, and
56% at 30 mm Hg) (63). Abraham et al. (22) used an
invasive, implantable hemodynamic monitoring device in
the CHAMPION (CardioMEMS Heart Sensor Allows
Monitoring of Pressure to Improve Outcomes in NYHA
Class III Heart Failure Patients) trial and showed a 39%
reduction in HF-related hospitalizations compared with the
control group over 15 months (153 vs. 253; HR: 0.64; 95%
CI: 0.55 to 0.75; p  0.0001), with an acceptable safety
profile (22).Transplantation
Important reports in the area of heart transplantation
focused on patient selection for transplantation, strategies to
bridge patients with mechanical circulatory support, and
optimization of outcomes after transplantation by sex
matching and immunosuppression. Gorodeski et al. (64)
found that the Seattle Heart Failure Model provided mod-
est discrimination of risk for mortality or need for ventric-
ular assist device (VAD) implantation or urgent transplan-
tation. However, risk was underestimated in patients who
were ultimately listed as United Network of Organ Sharing
status 2 (64). Another risk model, the Heart Failure Survival
Score, was found to outperform peak oxygen consumption
in patients who had implantable cardioverter-defibrillators
(ICDs) and/or cardiac resynchronization therapy (CRT).
They postulated that perhaps a peak oxygen consumption
10 ml/kg/min rather than 14 ml/kg/min may be a more
useful discriminator in the device era. It was surprising to
note, however, that in this single-center study of 715
patients referred for transplantation evaluation, 46.6% had
no device therapy in place (65).
Two studies reported outcomes after transplantation in
patients who were bridged with mechanical circulatory
support. John et al. (66) found no difference in survival
between patients who were bridged with continuous-flow
VADs versus no VADs and no difference in survival on the
basis of the duration of VAD support. Nativi et al. (67)
analyzed data for 8,557 patients from the International
Society for Heart and Lung Transplantation Registry,
finding no significant difference in post-transplant survival
between patients bridged with pulsatile versus continuous-
flow VADs between 2004 and 2008. Graft rejection and
survival rates were similar between both VAD groups and
non-VAD patients who underwent transplantation. In an-
other study, renal outcomes after heart transplantation in
patients who were bridged with VADs were dependent on
the level of renal function obtained during the time of
mechanical support, not on the level of renal function before
VAD implantation (68).
A retrospective single-center study confirmed that heart
transplantation patients with donor-recipient sex mismatch
have statistically significantly lower rates of survival (69), a
finding that has yet to change practice. Finally, the TICTAC
(Tacrolimus in Combination, Tacrolimus Alone Com-
pared) trial was published, which demonstrated equivalent
composite biopsy scores, allograft vasculopathy, and 3-year
survival between patients treated with tacrolimus alone
versus tacrolimus plus mycophenolate (70). If confirmed in
a larger trial with longer follow-up, chronic immunosup-
pressive strategies may change.
Mechanical Circulatory Support
The year saw an important report focusing on health-related
quality of life and exercise tolerance in patients after heart
363JACC Vol. 60, No. 5, 2012 Owens and Jessup
July 31, 2012:359–68 The Year in Heart Failuretransplantation compared with those during VAD support
(71). Quality of life and exercise capacity increased in both
groups over the time course of the study, but after adjust-
ment, transplantation patients showed higher exercise tol-
erance compared with the VAD group. Nevertheless, these
data, coupled with those of Starling et al. (72), who
prospectively examined the outcome of patients bridged to
transplantation with the commercially available HeartMate II
device (Thoratec Corporation, Pleasanton, California),
demonstrated the utility of VADs in the advanced HF
population. The percent of patients reaching transplanta-
tion, cardiac recovery, or ongoing VAD support by 6
months was 91% for the commercial device, and the
Kaplan-Meier survival for patients remaining on support at
1 year was 85% (72). Quality of life was significantly
improved at 3 months of support and sustained through 12
months compared with baseline.
The improved outcomes with continuous-flow VADs
have been tempered by a growing body of research on
adverse effects, including multiple reports of acquired von
Willebrand syndrome after VAD placement, manifested by
severe impairment of platelet aggregation as well as a loss of
large vonWillebrand multimers (73,74). Although it appears
that these hematologic changes occur in the majority of
patients, not all patients have clinical bleeding. And a contro-
versial report by Schaffer et al. (75) argued that although
patients with continuous-flow VADs have shown decreases in
infectious complications, this was likely related to increased
provider experience, not the newer technology. Cowger et al.
(76) produced 1 in a series of reports showing that aortic
insufficiency progresses over time in continuous-flow VAD–
supported patients, and Goda et al. (77) described their further
attention to the aortic valve, proposing that additional proce-
dures to the aortic valve at the time of VAD placement are
feasible. Finally, Piacentino et al. (78) focused on the tricuspid
valve, demonstrating that tricuspid regurgitation is not reduced
immediately after VAD implantation; significant tricuspid
regurgitation was associated with longer post-implantation
inotropic support and length of hospital stay.
Strategies to improve outcomes include a careful scrutiny
of patient selection for continuous-flow VAD therapy.
Boyle et al. (79) analyzed data from the Interagency Reg-
istry for Mechanically Assisted Circulatory Support and
demonstrated that less acutely ill but functionally impaired
patients with HF receiving continuous-flow VADs had
longer survival and shorter lengths of stay compared with
patients who were more acutely ill, as stratified by the
registry’s patient profile schema. This finding, which was
not entirely surprising, is nonetheless important to remem-
ber as we consider the optimal timing of VAD therapy with
respect to progression of HF symptoms. Adamson et al.
(80) argued that properly selected patients over 70 years of
age had good functional recovery, survival, and quality of life
at 2 years with current VAD technology. Even perioperative
strategies paled in comparison with proper patient selection.
In a randomized controlled trial evaluating the effect ofinhaled nitric oxide in patients undergoing VAD implanta-
tion, the use of nitric oxide at 40 ppm in the perioperative
phase did not achieve significance for the primary end point
of reduction in right ventricular dysfunction (81). Similarly,
secondary end points of time on mechanical ventilation,
hospital or intensive care unit stay, and the need for right
ventricular VAD support were not significantly improved.
Efforts to recover the failing heart are ongoing, given the
mixed news about long-term mechanical circulatory support.
Birks et al. (82) repeated their studies in myocardial recovery,
showing that reversal of end-stage HF secondary to nonisch-
emic cardiomyopathy could be achieved in a substantial pro-
portion of patients with nonpulsatile flow through the use of a
combination of mechanical and pharmacological therapy. A
less sustained approach to patients in shock has been facilitated
by the use of percutaneous, nondurable circulatory support,
reviewed in 2 reports (83,84).
Novel Therapeutics
There were several studies investigating new therapeutic
strategies. The Rheos phase III trial evaluated the effect of
baroreflex activation therapy on systolic blood pressure in
patients with resistant hypertension, demonstrating sus-
tained efficacy and safety of the device (85). Another
emerging therapy for resistant hypertension targeted renal
sympathetic denervation (86). A smaller phase II study
evaluated chronic vagus nerve stimulation in systolic HF
and showed significant improvements in quality of life,
6-min walking distance, and LV size and function. How-
ever, a fairly high rate of adverse events was noted, suggest-
ing the need for a larger, controlled trial (87). In the phase II
CUPID (Calcium Upregulation by Percutaneous Adminis-
tration of Gene Therapy in Cardiac Disease) study, the
investigators suggested safety and potential efficacy of per-
cutaneous administration of gene therapy in patients with
advanced HF, providing rationale to continue with a larger
investigation (88).
Cardiorenal Syndrome
As investigations continue into the often observed link
between worsening renal function and adverse prognosis,
several studies explored the role of renal biomarkers in
predicting cardiorenal syndrome. Cystatin C was found to
be a marker of acute kidney injury in the first 48 h after
hospitalization for HF. Furthermore, a rise in cystatin C by
0.3 mg/l was an independent predictor of 90-day mortal-
ity (adjusted odds ratio: 2.8; 95% CI: 1.2 to 6.7; p  0.02)
(89). In a second, small biomarker study, both urinary
kidney injury molecule-1 (p  0.001) and urinary N-acetyl-
beta-D-glucosaminidase (p  0.01) concentrations rose
significantly after diuretic agents were withdrawn temporar-
ily from patients with stable HF, whereas serum and urinary
neutrophil gelatinase–associated lipocalin levels and serum
creatinine were not significantly affected. After restarting
diuretic therapy, both urinary kidney injury molecule-1 and
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to baseline (both p values 0.05), suggesting that these
renal biomarkers may be sensitive to subclinical changes in
volume status (90). It is not yet clear how these biomarkers
can be used to alter clinical practice or outcomes.
Arrhythmias and Device Therapy for Heart Failure
The year witnessed many investigations into the benefits of
and appropriate patient selection for ICD and CRT. The
National Cardiovascular Data Registry revealed that in
patients with ICDs, 22.5% did not meet evidence-based
criteria for implantation (91), while nearly 1 in 4 patients
receiving CRT devices did not fulfill guideline-based indi-
cations (92). These sobering statistics have often been
coupled with the concern that as many as 40% to 80% of
patients eligible for ICDs fail to receive them, especially
among women and minorities. On a more optimistic note,
LaPointe et al. (93) reported that after a detailed chart
review, the true rate of ICD underuse may be substantially
lower than previous estimates, and adjusting for ICD
eligibility criteria virtually abolished patient sex and age
disparities in ICD therapy. Fewer vascular complications
with ICD implantation may be a reality with entirely
subcutaneous ICDs, which consistently detected and con-
verted ventricular fibrillation induced during electrophysio-
logical testing (94).
The theme of appropriate patient selection to optimize
outcomes after CRT implantation was reiterated in many
studies. Tang et al. and the RAFT (Resynchronization-
Defibrillation for Ambulatory Heart Failure) trial investigators
(26) confirmed the efficacy of CRT in patients with milder
HF; subsequent meta-analyses underscored the lessons
learned from the available CRT trials (95,96). Additional
studies from the MADIT–CRT (Multicenter Automatic
Defibrillator Implantation Trial With Cardiac Resynchro-
nization Therapy) trial emphasized the greater effectiveness
of CRT in women (97) and the strong association between
CRT-induced reverse LV remodeling and the beneficial
outcomes of fewer HF hospitalizations (98) as well as the
decreased risk for ventricular tachyarrhythmias (99). A
series of reports examined predictors of CRT success or
failure: Bilchick et al. (100) noted that right bundle branch
block, ischemic cardiomyopathy, NYHA functional class IV
status, and advanced age were powerful adjusted predictors
of poor outcomes; a related study from the Netherlands
showed that larger baseline LV dyssynchrony predicted
superior long-term survival, whereas discordant LV lead
position and myocardial scar predicted worse outcome
(101). Two additional investigations emphasized the impor-
tance of LV lead position on clinical outcomes (102) and
prognosis (103).
Heart Failure With Normal Ejection Fraction
Our understanding of the pathophysiology of HF with
normal ejection fraction (HFNEF) was advanced by 2 sexercise studies with concomitant invasive hemodynamic
monitoring (104,105). Although the 2 studies did not
agree on all findings, they suggest that exercise testing
with simultaneous right-heart catheterization may be
useful in exploring the diverse pathophysiologic mecha-
nisms in HFNEF.
Despite a better understanding of the hemodynamic
derangements in HFNEF, an efficacious pharmacologic
treatment has not been identified. A small study showed
that patients with HFNEF had elevations in specific pa-
rameters of collagen content that correlated with impaired
tissue Doppler (106), but the RAAM-PEF (Randomized
Aldosterone Antagonism in Heart Failure With Preserved
Ejection Fraction) trial was not associated with symptom-
atic reduction, although significant reductions in markers of
collagen turnover and improvement in diastolic function
were observed (107). Enalapril also proved unhelpful in
HFNEF in a randomized double-blind trial (108). Al-
though patients with HFNEF commonly have symptoms
with exercise, exercise training improved peak and submaxi-
mal exercise capacity in older patients with HFNEF (109).
rocesses and Quality of Care
ebate continues regarding the best measure of quality of
are, including whether or not readmission is an accurate
easure of the quality of care delivered (110). Several
ublications addressed process of care in HF (111–114),
eginning with a study that showed the association between
ncreased experience in managing HF, measured by an
nstitution’s volume, and higher quality of care and out-
omes, albeit at a higher cost (115). Lee et al. (112)
emonstrated that collaborative care, with a cardiologist and
rimary care physician, was associated with reduced mor-
ality compared with primary care alone (HR: 0.79; 95% CI:
.63 to 1.00; p  0.45) after discharge from the emergency
department. A staffing survey revealed that most HF prac-
tices (43%) have 4 staff members, with 4 to 10 staff
members in 34% of practices and only 23% of practices
having 11 staff members (116). The care of complicated
patients with HF is time intensive, and optimal resource
utilization of caregivers has not yet been defined.
Three reports from the IMPROVE–HF (Registry to
Improve the Use of Evidence-Based Heart Failure Thera-
pies in the Outpatient Setting) provided insight into strat-
egies for increasing evidence-based care. Seven quality
measures were assessed in 34,810 participants, and interven-
tions included decision support tools, structured improvement
strategies, and audits with feedback, resulting in statistically
significant improvements in beta-blocker use, aldosterone an-
tagonist use, CRT, ICD implantation, and HF education
(117). Furthermore, HF measures (angiotensin-converting
nzyme inhibitor and beta-blocker use, anticoagulation for
trial fibrillation, CRT and ICD use, and HF education)
ere found to be independently associated with 24-month
urvival, with each 10% improvement in composite care
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(113). The sobering, but not surprising, finding that doses
of all evidence-based therapies remain lower in real-world
practice than in clinical trials was also confirmed (114).
Conclusions
Another year concludes without a paradigm-changing ad-
vance in the treatment or prevention of HF. In the absence
of new therapies, it is apparent that clinicians must focus on
improving the continuity of care that patients with HF
receive, beginning in the emergency department, through
the hospitalization, and to the discharge process, using a
multidisciplinary group of care givers. The transition of our
patients outside the hospital is even more important, so that
communication and plans of care are optimized. We need to
identify the critical components of this care at every junc-
ture; best practices should be celebrated and adopted.
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